MOUNTAINSIDE, NJ--(Marketwire - April 22, 2010) -
Highlighted Links |
Proteoderm, Inc. |
Proteonomix, Inc. |
The Company has traded on the Pink Sheets and more recently on the OTCQB. Since October 5, 2009, it has filed reports with the SEC, including quarterly reports on Form 10-Q, an annual report on Form 10-K and reports on Form 8-K. In addition, its affiliates have reported their acquisition and sale of Proteonomix securities on Form 3 and Form 4.
Michael Cohen, President, stated: "We have always tried to be transparent in the disclosure of our business and finances and intend to be current in reports filed with the SEC. Our receipt of this SEC no-comment letter on our registration statement allows us the opportunity to list on the OTCBB market. An OTCBB listing will add to the credibility of the disclosure of our technological and therapeutic advances, and also exposes our company to clients of firms that do not presently allow their representatives to recommend our common stock. Finally, a listing on the OTCBB will provide a greater opportunity for institutions to become involved in PROT."
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteonomix has facilities at a number of academic institutions. Its subsidiary, Proteoderm has developed a line of anti-aging cosmetics. Please visit www.proteonomix.com, www.proteoderm.com, www.otcqb.com and www.sec.gov.
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release relating to its OTCBB listing constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.
Contact:
Michael Cohen
Proteonomix, Inc.
(973) 544-6116